Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
22 participants
OBSERVATIONAL
2023-01-06
2023-12-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Entia Liberty: Accuracy and Precision
NCT05025124
Entia Liberty: Capillary Validation
NCT05025111
Capillary Blood Accuracy
NCT06544070
Liberty Analyzer WBC System: Reference Interval Study
NCT07031882
Lymphedema Sensor Technology Development Study
NCT06778837
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patient Group
Entia Liberty
Home monitoring blood analyser
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Entia Liberty
Home monitoring blood analyser
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Adequate English language skills (not requiring a translator) to participate in participant training and use the Liberty device
* Patients willing and able to perform capillary blood self-testing at the same frequency as routine full blood count monitoring
* Patients capable of providing informed consent before attending training
* Patients able to attend a 1-hour virtual training session within 2 weeks of joining the study
* Patients with a home Wi-Fi network or with adequate coverage at home via a 4G network
* Patients with access to a laptop or smartphone to facilitate training
* Patients with a diagnosis of ovarian or breast cancer
* Patients whose HCPs can confirm are undergoing systemic anti-cancer treatments within two weeks of enrolment, with treatment expected to continue for at least two cycles
Exclusion Criteria
* Patients with eyesight or hearing limitations or other disabilities that preclude the use of the Liberty device or participation in training unless they have a nominated caregiver who is capable of assisting with each test
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Entia Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Christie NHS Foundation Trust
Manchester, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
317614
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.